Gentian Diagnostics AS (OSL:GENT) PE Ratio (TTM): At Loss (As of Jul. 12, 2026)


OSL:GENT Gentian Diagnostics AS OSL:GENT
74 GF Score
Price kr38.40
GF Value kr59.17
Valuation Significantly Undervalued
View Full Analysis

What is Gentian Diagnostics AS PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-12), Gentian Diagnostics AS's share price is kr38.40. Gentian Diagnostics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.55. Therefore, Gentian Diagnostics AS's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Gentian Diagnostics AS's PE Ratio (TTM) or its related term are showing as below:

OSL:GENT' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: 20.93   Max: 330.77
Current: At Loss


During the past 13 years, the highest PE Ratio (TTM) of Gentian Diagnostics AS was 330.77. The lowest was 0.00. And the median was 20.93.


OSL:GENT's PE Ratio (TTM) is ranked worse than
100% of 436 companies
in the Medical Devices & Instruments industry
Industry Median: 26.1 vs OSL:GENT: At Loss

Gentian Diagnostics AS's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was kr0.29. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.55.

As of today (2026-07-12), Gentian Diagnostics AS's share price is kr38.40. Gentian Diagnostics AS's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.55. Therefore, Gentian Diagnostics AS's PE Ratio without NRI for today is At Loss.

During the past 13 years, Gentian Diagnostics AS's highest PE Ratio without NRI was 330.77. The lowest was 0.00. And the median was 20.93.

Gentian Diagnostics AS's EPS without NRI for the three months ended in Jun. 2026 was kr0.29. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.55.

During the past 12 months, Gentian Diagnostics AS's average EPS without NRI Growth Rate was -120.70% per year.

During the past 13 years, Gentian Diagnostics AS's highest 3-Year average EPS without NRI Growth Rate was 21.30% per year. The lowest was -60.70% per year. And the median was -15.80% per year.

Gentian Diagnostics AS's EPS (Basic) for the three months ended in Jun. 2026 was kr0.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was kr-0.55.


Gentian Diagnostics AS  (OSL:GENT) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Gentian Diagnostics AS PE Ratio (TTM) Related Terms


Gentian Diagnostics AS PE Ratio (TTM) Historical Data

* Premium members only.

The historical data trend for Gentian Diagnostics AS's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gentian Diagnostics AS PE Ratio (TTM) Chart

Gentian Diagnostics AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss 13.66 65.58

Gentian Diagnostics AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.06 20.00 65.58 At Loss At Loss

OSL:GENT vs ABT, SYK, MDT: PE Ratio (TTM) Comparison

For the Medical Devices subindustry, Gentian Diagnostics AS's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS PE Ratio (TTM) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's PE Ratio (TTM) falls into.


OSL:GENT
74GF Score
Gentian Diagnostics AS OSL:GENT
PE Ratio (TTM) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gentian Diagnostics AS PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Gentian Diagnostics AS's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=38.40/-0.550
=At Loss

Gentian Diagnostics AS's Share Price of today is kr38.40.
Gentian Diagnostics AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.55.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Is Gentian Diagnostics AS (OSL:GENT) Overvalued in 2026?

Based on GuruFocus' analysis, Gentian Diagnostics AS stock appears to be undervalued. The current stock price of kr38.40 is trading 35.1% below its estimated GF Value™ of kr59.17. GuruFocus considers Gentian Diagnostics AS to be Significantly Undervalued.

Key valuation signals for OSL:GENT:

  • PE Ratio (TTM): At Loss
  • GF Value™: kr59.17 vs. price of kr38.40 (35.1% below fair value)
  • GF Score™: 74/100

No single metric tells the full story. See the OSL:GENT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gentian Diagnostics AS Business Description

Other Exchanges GENTOo:Sweden6FK:Germany
Address Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in vitro diagnostic reagents (IVD) for medical diagnostics and research. Its portfolio and pipeline of reagents span areas such as inflammation, severe infections, kidney diseases, heart failure, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP, among others. Geographically, it generates a majority of its revenue from Europe, followed by Asia and the United States of America.
74GF Score

Get the complete analysis for OSL:GENT

PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr38.40
Price
kr59.17
GF Value